# A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

> **NCT05169684** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 10 (actual)

## Conditions studied

- Prostatic Neoplasms, Castration-Resistant

## Interventions

- **BIOLOGICAL:** BMS-986218
- **DRUG:** Docetaxel
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT05169684
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-14
- **Primary completion:** 2023-12-06
- **Final completion:** 2023-12-06
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05169684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05169684, "A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05169684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*